3-MATIDAPotent, selective mGlu1 antagonist CAS# 518357-51-2 |
- UNC 0224
Catalog No.:BCC2430
CAS No.:1197196-48-7
- 3-Deazaneplanocin A (DZNep) hydrochloride
Catalog No.:BCC3604
CAS No.:120964-45-6
- UNC0638
Catalog No.:BCC1135
CAS No.:1255580-76-7
- UNC 0631
Catalog No.:BCC4143
CAS No.:1320288-19-4
- Chaetocin
Catalog No.:BCC2429
CAS No.:28097-03-2
- BIX 01294
Catalog No.:BCC1131
CAS No.:935693-62-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 518357-51-2 | SDF | Download SDF |
PubChem ID | 10398360 | Appearance | Powder |
Formula | C8H9NO4S | M.Wt | 215.23 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in 1eq. NaOH and to 50 mM in DMSO | ||
Chemical Name | 5-[amino(carboxy)methyl]-4-methylthiophene-2-carboxylic acid | ||
SMILES | CC1=C(SC(=C1)C(=O)O)C(C(=O)O)N | ||
Standard InChIKey | KOMWRBFEDDEWEP-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C8H9NO4S/c1-3-2-4(7(10)11)14-6(3)5(9)8(12)13/h2,5H,9H2,1H3,(H,10,11)(H,12,13) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent metabotropic glutamate mGlu1 receptor antagonist (IC50 = 6.3 μM at rat mGlu1a). Displays ≥ 40-fold selectivity over other receptors: mGlu5, mGlu2, mGlu4a (IC50 > 300 μM), NMDA and AMPA (IC50 = 250 μM). Neuroprotective in cultured murine cortical cells and rat hippocampal slice cultures in vitro. Reduces the volume of ischemia-induced brain infarcts in rats following systemic administration in vivo. |
3-MATIDA Dilution Calculator
3-MATIDA Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.6462 mL | 23.231 mL | 46.4619 mL | 92.9238 mL | 116.1548 mL |
5 mM | 0.9292 mL | 4.6462 mL | 9.2924 mL | 18.5848 mL | 23.231 mL |
10 mM | 0.4646 mL | 2.3231 mL | 4.6462 mL | 9.2924 mL | 11.6155 mL |
50 mM | 0.0929 mL | 0.4646 mL | 0.9292 mL | 1.8585 mL | 2.3231 mL |
100 mM | 0.0465 mL | 0.2323 mL | 0.4646 mL | 0.9292 mL | 1.1615 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Angiotensin (1-7)
Catalog No.:BCC1029
CAS No.:51833-78-4
- Angiotensin 1/2 + A (2 - 8)
Catalog No.:BCC1037
CAS No.:51833-76-2
- UMI-77
Catalog No.:BCC5567
CAS No.:518303-20-3
- 2',4'-Dihydroxychalcone
Catalog No.:BCN5647
CAS No.:1776-30-3
- KX1-004
Catalog No.:BCC5440
CAS No.:518058-84-9
- Raltegravir (MK-0518)
Catalog No.:BCC2137
CAS No.:518048-05-0
- Dihydrooxoepistephamiersine
Catalog No.:BCN5646
CAS No.:51804-69-4
- Oxoepistephamiersine
Catalog No.:BCN5645
CAS No.:51804-68-3
- Nimesulide
Catalog No.:BCC4435
CAS No.:51803-78-2
- 3,3'-Di-O-methylellagic acid 4'-glucoside
Catalog No.:BCN1431
CAS No.:51803-68-0
- Isomaculosidine
Catalog No.:BCN7069
CAS No.:518-96-7
- Cycleanine
Catalog No.:BCN8445
CAS No.:518-94-5
- Allamandicin
Catalog No.:BCN4625
CAS No.:51838-83-6
- Licoricone
Catalog No.:BCN6818
CAS No.:51847-92-8
- 7-O-Methyleriodictyol
Catalog No.:BCN5648
CAS No.:51857-11-5
- Axillarin
Catalog No.:BCN8102
CAS No.:5188-73-8
- Pizotifen Malate
Catalog No.:BCC4825
CAS No.:5189-11-7
- Matrine
Catalog No.:BCN5650
CAS No.:519-02-8
- Benzoylecgonine
Catalog No.:BCN1909
CAS No.:519-09-5
- Ellipticine
Catalog No.:BCC7665
CAS No.:519-23-3
- Maclurin
Catalog No.:BCN5651
CAS No.:519-34-6
- Sulochrin
Catalog No.:BCN6959
CAS No.:519-57-3
- 4-(N-Methyl)-aminoantipyrine
Catalog No.:BCC8652
CAS No.:519-98-2
- Dehydrohautriwaic acid
Catalog No.:BCN7586
CAS No.:51905-84-1
Stereoselective synthesis and preliminary evaluation of (+)- and (-)-3-methyl-5-carboxy-thien-2-yl-glycine (3-MATIDA): identification of (+)-3-MATIDA as a novel mGluR1 competitive antagonist.[Pubmed:14871500]
Farmaco. 2004 Feb;59(2):93-9.
The synthesis of the (+)- and (-)-isomers of 3-methyl-5-carboxy-thyen-2-yl-glycine (3-MATIDA), heterocyle isosters of carboxyphenylglycines (CPGs), a known class of competitive metabotropic glutamate receptors, was accomplished by a stereoselective Ugi condensation. The two isomers were tested as potential rat mGluR1 ligand and the (+) isomer was found to be a moderately potent antagonist, while the (-) one was inactive.
The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death.[Pubmed:12015200]
Neuropharmacology. 2002 May;42(6):741-51.
We examined the pharmacological properties of 3-methyl-aminothiophene dicarboxylic acid (3-MATIDA) by measuring second messenger responses in baby hamster kidney cells stably transfected with mGlu1a, mGlu2, mGlu4a or mGlu5a receptors and ionotropic glutamate receptor agonist-induced depolarizations in mouse cortical wedges. 3-MATIDA was a potent (IC(50)=6.3 microM, 95% confidence limits 3-15) and relatively selective mGlu1 receptor antagonist. When tested on mGlu2, mGlu4 or mGlu5 receptors its IC(50) was >300 microM. When tested in cortical wedges, however, 3-MATIDA was also able to antagonize AMPA or NMDA responses with an IC(50) of 250 microM. When present in the incubation medium of cultured murine cortical cells, 3-MATIDA (1-100 microM) significantly reduced the death of neurons induced by 60 min of oxygen and glucose deprivation (OGD), even when added up to 60 min after OGD. A similar neuroprotective activity was observed when 3-MATIDA was present at 10-100 microM in the medium of rat organotypic hippocampal slice cultures exposed to 30 min OGD. Systemic administration of 3-MATIDA (3-10 mg/kg, immediately and 1 h after the onset of ischemia) reduced the volume of brain infarcts following permanent middle cerebral artery occlusion in rats. Our results show that 3-MATIDA is a potent and possibly selective mGlu 1 receptor antagonist that may be considered as a novel prototype neuroprotective agent.
Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neurotransmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity?[Pubmed:12213266]
Neuropharmacology. 2002 Aug;43(2):119-30.
Selective antagonists of mGlu1 metabotropic glutamate receptors attenuate neuronal death in models of cerebral ischemia. Because GABAergic mechanisms have recently been proposed to contribute to these neuroprotective effects, we examined the effects of selective mGlu1 antagonists characterized in our laboratory on GABAergic transmission in three different models of neuropathology. In rat organotypic hippocampal slices exposed to oxygen-glucose deprivation, the mGlu1 antagonists AIDA, CBPG and 3-MATIDA reduced CA1 pyramidal cell loss when added to the medium during the insult and the subsequent recovery period. This effect was mimicked by the GABA(A) and GABA(B) agonists muscimol and baclofen and partially prevented by the antagonists bicuculline and CGP 55845. In gerbils subjected to global ischemia, protection of CA1 pyramidal cells by transdialytic perfusion of AIDA and CBPG was associated with a significant increase in the basal and ischemic output of GABA and minor changes in the output of glutamate. In a mouse cortical wedge model, both muscimol and 3-MATIDA reduced the frequency of spontaneous bursts induced by 4-aminopyridine and this reduction was prevented by co-perfusion with bicuculline. Taken together, our results suggest that the release of GABA, and the subsequent activation of GABA receptors, may contribute to the attenuation of post-ischemic neuronal damage and epileptiform activity induced by mGlu1 receptor antagonists.